Lyell Immunopharma, Inc. (LYEL) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Lyell Immunopharma is a clinical-stage cell therapy company focused on developing next-generation CAR T-cell therapies for hematologic malignancies and solid tumors. The company's lead program, LYL314 (formerly IMPT-314), is a dual-targeting CD19/CD20 CAR T-cell candidate currently in Phase 1/2 clinical trials for relapsed/refractory large B-cell lymphoma. In October 2024, the company completed the acquisition of ImmPACT Bio USA Inc., acquiring LYL314 and transitioning its manufacturing to Lyell's LyFE Manufacturing Center in Bothell, Washington.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $7 | $3 |
| Net Loss | $(52,195) | $(60,667) |
| Loss Per Share (Basic & Diluted) | $(0.18) | $(0.24) |
| Research & Development Expenses | $43,447 | $43,174 |
| General & Administrative Expenses | $14,046 | $13,494 |
| Cash, Cash Equivalents & Marketable Securities | $301,177 | $370,527 |
| Net Cash Used in Operating Activities | $(54,738) | $(42,016) |
| Accumulated Deficit | $(1,397,301) | $(1,062,779) |
Note: The company has no debt outstanding as of March 31, 2025.
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by approximately $8.5 million compared to Q1 2024. This improvement was primarily driven by the absence of a $13.0 million impairment charge on other investments recorded in Q1 2024.
- Operating Expenses: Total operating expenses increased slightly by $1.8 million. R&D expenses remained relatively flat, with a $3.1 million increase in personnel costs (due to severance from the West Hills facility closure) offset by reductions in research activities and success payment expenses.
- Interest Income: Interest income, net, decreased by $2.9 million to $3.9 million, attributed to lower interest rates and reduced cash balances.
- Other Income: Other income, net, increased to $1.3 million, driven by a $1.2 million gain from the change in fair value of contingent consideration payable related to the ImmPACT acquisition.
- Liquidity: Total cash, cash equivalents, and marketable securities decreased by approximately $69 million from the prior year, reflecting operating cash burn and net purchases of marketable securities.
Guidance, Outlook, and Risks
- Clinical Outlook: The company expects to initiate a pivotal trial for LYL314 in mid-2025 for third-line or later settings and another pivotal trial by early 2026 for second-line settings. New clinical data is expected to be presented in June 2025.
- Liquidity Runway: Management believes existing cash, cash equivalents, and marketable securities ($330.1 million as of March 31, 2025) are sufficient to fund operations for at least the next 12 months.
- Manufacturing Transition: Manufacturing for LYL314 has been successfully transferred to the LyFE facility in Bothell, WA. Consequently, the West Hills, CA facility was closed in March 2025, resulting in a reduction of approximately 73 employees.
- Nasdaq Compliance Risk: The company received a notification from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement. Management is monitoring the situation and may implement a reverse stock split to regain compliance.
- Success Payments: The company has contingent success payment obligations to Fred Hutch and Stanford based on stock price milestones. As of March 31, 2025, no payments were incurred as the stock price remained below the required thresholds.
Key Facts for Investor Verification
- Stock Price & Listing Status: Verify the current trading price of LYEL and the status of the Nasdaq delisting notice, including the potential approval of a reverse stock split.
- ImmPACT Integration: Confirm the successful transition of LYL314 manufacturing to the LyFE facility and the associated cost savings or one-time charges related to the West Hills closure.
- Clinical Trial Enrollment: Monitor enrollment rates and safety data for the ongoing Phase 1/2 trial of LYL314, particularly regarding the dual-targeting mechanism's efficacy against antigen escape.
- Capital Requirements: Assess the company's burn rate and the potential need for additional equity financing beyond the 12-month runway, especially given the upcoming pivotal trials.
- Contingent Liabilities: Review the fair value of the $6.4 million contingent consideration payable (12.5 million shares) and success payment liabilities, which fluctuate with the company's stock price.